PharmaMar

“In certain circumstances, pharmaceutical companies, with the agreement of the relevant health authorities, may make a drug available before it is officially approved. This is usually limited to cases where the disease represents an unmet medical need. These programs may also be called "compassionate use" or "expanded access." For example, our current compassionate use program has recruited over 3,000 patients from many countries. Ask your doctor if there are any such programs available in your area and if it would be suitable for you, or email us at compassionateuse-LUR@pharmamar.com indicating your interest and your country. The inquiry should come from a healthcare professional.”

PharmaMar is launching this study after evaluating the data obtained in compassionate use programs with plitidepsin in more than 70 patients with this profile, which suggest that this could be a well-tolerated treatment, with potential antiviral efficacy in immunosuppressed patients with COVID-19.

Patients in the other European Countries currently can only benefit from lurbinectedin through compassionate use or in a clinical trial.

Sales in oncology have increased by 25% to €19.0 million. This increase is primarily due to commercial sales of Zepzelca in Europe amounting to €4.2 million, as well as raw material sales to our partners, both for Yondelis and Zepzelca, totaling €3.3 million, and revenue from the "early access" program, which increased by 12% to €6.3 million. These latter revenues mainly come from France, although there are also ongoing "early access" programs in countries such as Spain and Austria.

Revenue from lurbinectedin in Europe under the early access amounted to €12.3 million in the first half of 2024, compared to €21.0 million recorded up to June 30th, 2023.

Revenues from the early access program grew to €29.7 million at year-end, compared with €15.5 million in 2022. These revenues come mainly from France, although other early access programs are also open in countries such as Spain and Austria.